Outlook Therapeutics, Inc. (NASDAQ:OTLK) Given Consensus Rating of “Moderate Buy” by Brokerages

Outlook Therapeutics, Inc. (NASDAQ:OTLK) has been given an average rating of “Moderate Buy” by the eight brokerages that are currently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold recommendation and seven have assigned a buy recommendation to the company. The average twelve-month price objective among analysts that have issued a report on the stock in the last year is $46.43.

Separately, HC Wainwright restated a “buy” rating and set a $30.00 price objective on shares of Outlook Therapeutics in a research report on Friday, May 17th.

Institutional Trading of Outlook Therapeutics

A hedge fund recently bought a new stake in Outlook Therapeutics stock. Rosalind Advisors Inc. acquired a new position in Outlook Therapeutics, Inc. (NASDAQ:OTLK) in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 311,775 shares of the company’s stock, valued at approximately $3,723,000. Outlook Therapeutics makes up approximately 3.5% of Rosalind Advisors Inc.’s holdings, making the stock its 14th largest position. Rosalind Advisors Inc. owned approximately 2.40% of Outlook Therapeutics as of its most recent filing with the Securities and Exchange Commission. 11.20% of the stock is owned by institutional investors and hedge funds.

Outlook Therapeutics Price Performance

Shares of OTLK stock opened at $8.56 on Monday. The company has a market capitalization of $200.39 million, a price-to-earnings ratio of -0.75 and a beta of 0.71. Outlook Therapeutics has a one year low of $4.00 and a one year high of $34.80. The company’s fifty day moving average price is $7.68 and its 200-day moving average price is $8.09.

Outlook Therapeutics (NASDAQ:OTLK) last announced its quarterly earnings data on Wednesday, May 15th. The company reported ($1.55) EPS for the quarter, missing the consensus estimate of ($0.88) by ($0.67). Equities research analysts expect that Outlook Therapeutics will post -4.08 earnings per share for the current fiscal year.

About Outlook Therapeutics

Outlook Therapeutics, Inc, operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.